Bibliographic Details
| Title: |
Dermatosis pustulosa subcórnea tratada exitosamente con colchicina. |
| Alternate Title: |
SUBCORNEAL PUSTULAR DERMATOSIS SUCCESSFULLY TREATED WITH COLCHICINE. |
| Authors: |
Carolina Llamas-Castellanos, Bruny1 bllamasc@unicartagena.edu.co, Hernández-Buitrago, Stephanie1, Viviana Meneses-Gaviria, Sandra1, Camacho-Chaljub, Francisco2 |
| Source: |
Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. abr-jun2025, Vol. 33 Issue 2, p1-5. 5p. |
| Subjects: |
TUMOR necrosis factors, COLCHICINE, MONOCLONAL antibodies, NEUTROPHILS, DAPSONE |
| Abstract (English): |
The subcorneal pustular dermatosis, also known as Sneddon-Wilkinson disease, is a rare, benign, although recurrent condition classified within the group of neutrophilic dermatoses. Its pathogenesis remains unclear. Clinically, pustules appear on the trunk and intertriginous areas, rarely on acral locations. Histologically, subcorneal collections of neutrophils form pustules. While dapsone remains the treatment of choice, this case report highlights a successful alternative treatment using colchicine, a well-established second-line drug, although multiple treatments have been described today, among the most recent, for example, adalimumab, a monoclonal antibody against tumor necrosis factor α (TNF-α). Colchicine is accessible, safe, and effective, and should be considered among the first lines of treatment. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
La dermatosis pustulosa subcórnea, o enfermedad de Sneddon-Wilkinson, es una enfermedad poco frecuente y benigna, aunque recurrente, que se encuentra dentro del grupo de las dermatosis neutrofílicas. Su patogenia aún no ha sido esclarecida. Clínicamente observamos pústulas en el tronco y las áreas intertriginosas, rara vez acrales. En la biopsia, hay colecciones subcorneales de neutrófilos que forman pústulas. El tratamiento de elección continúa siendo la dapsona; sin embargo, con este reporte se pretende exponer un caso clínico tratado de forma exitosa con colchicina, un medicamento de segunda línea, aunque hoy en día se han descrito múltiples tratamientos, de los más recientes, por ejemplo, adalimumab, un anticuerpo monoclonal antifactor de necrosis tumoral α (FNT-α). La colchicina es un medicamento de fácil acceso, seguro y eficaz que debe tenerse en cuenta dentro de las primeras líneas de tratamiento. [ABSTRACT FROM AUTHOR] |
|
Copyright of Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica is the property of Asociacion Colombiana de Dermatologia y Cirugia Dermatologica and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
